NCT05544019 · Schrödinger, Inc.
Study of SGR-1505 in Mature B-Cell Neoplasms
What this study is about
The purpose of this study is to evaluate safety and how well patients handle the treatment and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
View original scientific description
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.
- Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 12 weeks.
Exclusion criteria
- The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit).
- Subject has previous invasive malignancy in the last 2 years.
- Subject has a known allergy to SGR-1505 or excipients of SGR-1505.
- Subject has symptomatic or active CNS involvement of disease.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.
Where
- Gilbert, Arizona
- Newark, Delaware
- Pompano Beach, Florida
- Boston, Massachusetts
- Hackensack, New Jersey
- Buffalo, New York
- New York, New York
- The Bronx, New York
- Durham, North Carolina
- Canton, Ohio
- Columbus, Ohio
- Portland, Oregon
And 4 more locations — see the full list below.
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Feb 13, 2026 · Source of record for eligibility and locations